[
    [
        {
            "time": "2023-10-01",
            "original_text": "智飞生物：正加紧开发AC-Hib疫苗冻干剂型",
            "features": {
                "keywords": [
                    "智飞生物",
                    "AC-Hib疫苗",
                    "冻干剂型",
                    "研发"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：正加紧开发AC-Hib疫苗冻干剂型",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "快讯|智飞生物：子公司独家疫苗再注册失利 公司股价与市值齐飞遭股东频繁减持 减持股份",
            "features": {
                "keywords": [
                    "智飞生物",
                    "子公司",
                    "独家疫苗",
                    "再注册失利",
                    "减持"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "快讯|智飞生物：子公司独家疫苗再注册失利 公司股价与市值齐飞遭股东频繁减持 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "智飞生物重磅品种注册再次遭拒 疫苗龙头近千亿市值岌岌可危？",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重磅品种",
                    "注册遭拒",
                    "市值风险"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物重磅品种注册再次遭拒 疫苗龙头近千亿市值岌岌可危？",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "智飞生物AC-Hib三联结合疫苗未获再注册 加速新剂型研发机构预计仅2020年短缺",
            "features": {
                "keywords": [
                    "智飞生物",
                    "AC-Hib三联结合疫苗",
                    "再注册失败",
                    "新剂型研发",
                    "短缺"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物AC-Hib三联结合疫苗未获再注册 加速新剂型研发机构预计仅2020年短缺",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "19药企参与新冠病毒疫苗研发，部分产品进入动物实验阶段",
            "features": {
                "keywords": [
                    "新冠病毒疫苗",
                    "研发",
                    "动物实验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "19药企参与新冠病毒疫苗研发，部分产品进入动物实验阶段",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "智飞生物一独家疫苗品种再注册遭拒，影响几何？",
            "features": {
                "keywords": [
                    "智飞生物",
                    "独家疫苗",
                    "再注册遭拒"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物一独家疫苗品种再注册遭拒，影响几何？",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "AC-Hib疫苗再注册失败影响避重就轻 疫苗龙头智飞生物千亿元市值会否昙花一现？",
            "features": {
                "keywords": [
                    "AC-Hib疫苗",
                    "再注册失败",
                    "市值风险"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AC-Hib疫苗再注册失败影响避重就轻 疫苗龙头智飞生物千亿元市值会否昙花一现？",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "智飞生物：子公司AC-Hib疫苗未获得再注册批件",
            "features": {
                "keywords": [
                    "智飞生物",
                    "子公司",
                    "AC-Hib疫苗",
                    "再注册失败"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物：子公司AC-Hib疫苗未获得再注册批件",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]